To The Moon

Have you jumped on any of these gainers, or missed the boat?

Which sector do you think will spawn the next batch of double-digit gainers: biotech breakthroughs or AI infrastructure?

Share your picks below!

The 2026 US stock market kicked off with intense volatility, but as of the end of February, the S&P 500 has recovered all losses, closing just 1.8% below its all-time high. Looking back at 2025, the index rose more than 16% for the year, delivering returns above its long-term average for the third consecutive year. Entering the new year, investors are eagerly anticipating this upward momentum to continue.

Amid sector rotation, companies with unique catalysts have stood out as market focal points. Year-to-date, biotech firms with major clinical progress in the healthcare sector, along with stocks in semiconductor manufacturing and artificial intelligence (AI) infrastructure, have performed particularly impressively. Below are six leading companies listed on major US exchanges (with a market cap of at least $1 billion) that have doubled in share price so far this year.

No. 1: $ImmunityBio, Inc.(IBRX)$ – Year-to-Date Gain: 393.9%

ImmunityBio is a biotech company focused on developing therapies and vaccines for cancer and infectious diseases. Its core drug, Anktiva, fights diseases by enhancing and mobilizing the body’s natural immune system. Currently, the company is testing Anktiva in combination with other drugs to treat various conditions such as cancer and Lynch syndrome. Since the start of 2026, ImmunityBio has commercially launched Anktiva in Saudi Arabia and established an Irish subsidiary to prepare for its European launch. Additionally, the company reported outstanding efficacy and safety data from clinical studies on non-Hodgkin’s lymphoma. A series of positive developments have ignited investor enthusiasm, driving IBRX’s share price to an astonishing 393.9% gain year-to-date.

No. 2: $Erasca, Inc.(ERAS)$ – Year-to-Date Gain: 267.2%

Erasca is a clinical-stage biotech company focusing on cancers driven by the RAS/MAPK pathway, with a pipeline covering colorectal cancer, non-small cell lung cancer, and melanoma. Its core assets include ERAS-0015, ERAS-4001, and ERAS-12, which aim to inhibit the RAS/MAPK signaling pathway. In January, Erasca announced positive clinical data for ERAS-0015, confirming partial responses in treating multiple tumor types with different RAS mutations. Furthermore, the therapy demonstrated encouraging safety and tolerability profiles. Although ERAS-0015 is still in Phase I trials, Erasca’s current $4.2 billion market cap makes it a potential acquisition target. Multiple catalysts have pushed ERAS’s share price up 267.2% in 2026.

No. 3: $Alumis Inc.(ALMS)$ – Year-to-Date Gain: 204.2%

Alumis is a clinical-stage biotech company specializing in oral small-molecule therapies for immune-mediated diseases. Its lead candidate, envudeucitinib (ESK-001), is being developed for moderate-to-severe plaque psoriasis and systemic lupus erythematosus. In early January, Alumis announced that envudeucitinib met all primary and secondary endpoints in a Phase III clinical trial for moderate-to-severe plaque psoriasis. The company also stated plans to submit a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) in the second half of 2026. The market widely expects the drug to gain approval and enter commercialization, driving ALMS’s share price to surge 204.2% in the first two months of this year.

No. 4: $SanDisk Corp.(SNDK)$ – Year-to-Date Gain: 167.6%

As a global leader in NAND flash semiconductor suppliers, SanDisk boasts a vertically integrated industrial chain, with the vast majority of its flash chips produced at manufacturing facilities in Japan. Since its spin-off from Western Digital in February 2025, the company’s share price has soared by over 1,000%. With surging demand for storage devices in AI data centers, SanDisk is regarded as an AI concept stock. Meanwhile, a shortage of NAND chips has led to sustained price increases, significantly improving the company’s profit margins. Driven by multiple factors, SNDK’s share price has risen 167.6% year-to-date.

No. 5: $Ichor Holdings Ltd.(ICHR)$ – Year-to-Date Gain: 158.0%

Ichor Holdings is a key subsystem and component supplier in the semiconductor capital equipment manufacturing sector, with core products including chemical delivery systems, gas panels, and precision-machined parts. In early February, the company released Q4 earnings that far exceeded market expectations and provided an impressive growth outlook. Management stated that as its profitability improvement strategy gradually takes effect, gross margins are expected to "improve significantly" in fiscal 2026. Analysts generally anticipate healthy growth in wafer equipment spending this year, creating tailwinds for Ichor’s business. The confluence of multiple positive factors has driven ICHR’s share price up 158.0% so far in 2026.

No. 6: $Kosmos(KOS)$ – Year-to-Date Gain: 156.7%

Kosmos Energy is a company focused on deepwater oil and gas exploration and production, with operations primarily in the United States, Ghana, Mauritania, and Senegal. In February, Kosmos announced the sale of its production assets in Equatorial Guinea to Panoro Energy for $180 million, plus potential contingent payments of up to $39.5 million. Just days before this asset divestiture announcement, Ghana’s parliament approved the extension of drilling licenses for the Jubilee and TEN offshore oilfields until 2040, meaning Kosmos will invest up to $2 billion in the Jubilee field and drill 20 new wells. A series of initiatives to optimize its asset portfolio and lock in long-term growth have driven KOS’s share price to surge 156.7% year-to-date.

From the above list, it’s clear that 2026’s early US stock leaders are mainly concentrated in two areas: biotech stocks that have experienced explosive growth driven by clinical breakthroughs or commercialization expectations; and semiconductor industry chain companies deeply involved in AI hardware infrastructure. When the market as a whole is near historical highs, individual stocks with independent catalysts often outperform the broader market. For investors, the ability to identify and seize these unique catalysts will be crucial in determining investment returns this year.

For SG users only, Welcome to open a CBA today and enjoy access to a trading limit of up to SGD 20,000 with unlimited trading on SG, HK, and US stocks, as well as ETFs.

🎉Cash Boost Account Now Supports 35,000+ Stocks & ETFs – Greater Flexibility Now

Find out more here.

Complete your first Cash Boost Account trade with a trade amount of ≥ SGD1000* to get SGD 688 stock vouchers*! The trade can be executed using any payment type available under the Cash Boost Account: Cash, CPF, SRS, or CDP.

Click to access the activity

Other helpful links:

• 💰Join the TB Contra Telegram Group to Get $10 Trading Vouchers Now🎉

• How to open a CBA. How to link your CDP account. Other FAQs on CBA. Cash Boost Account Website.